

HSAG ESRD Networks

Dialysis Facility Scorecard Measure Specifications—May 2025

Facility Scorecard Definitions

Network Measure: The Centers for Medicare & Medicaid Services (CMS)-established measure for Networks.

Network Goal: CMS-established goal for Networks.

Facility Baseline: Facility-specific count or rate at baseline for each measure.

Facility-Specific Goal: Facility-specific goal calculated by the Network for each measure based on the CMS-established goal.

Facility Remeasurement: Facility-specific rate or count based on May 2024–March 2025 cumulative data or March 2025 data (vaccinations).

Facility Percentile in the Network: Percentile ranking for the facility for each measure based on March 2025 remeasurement data.

Measure Specifications Table 1

Measure Name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods
Patients Added to the Transplant Waitlist	Patients added to a kidney transplant waiting list within the remeasurement period Due to CMS data requirements, if the count is 1–10, then the cell is blinded with "< 11."	None	Patients are attributed to the facility the patient was admitted to at the time s/he was added to a kidney transplant waiting list.	• Transplant facilities	<u>Baseline</u> : January 1, 2020– December 31, 2020 <u>Remeasurement</u> : May 1, 2024– March 31, 2025
Patients Receiving a Kidney Transplant	Patients who received a transplant within the remeasurement period Due to CMS data requirements, if the count is 1–10, then the cell is blinded with "< 11."	None	Patients are attributed to the facility the patient was admitted to immediately prior to the patient's admission to a transplant center.	• Transplant facilities	Baseline: January 1, 2020– December 31, 2020 Remeasurement: May 1, 2024– March 31, 2025



Measure Name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods
Incident Patients Using Home Modality	Number of dialysis patients with a New ESRD admission during the 90 days prior to or during the remeasurement period and a setting of Home beginning in the remeasurement period and within 90 days of admission Due to CMS data requirements, if the count is 1–10, then the cell is blinded with "< 11."	None	Patients whose initial treatment setting is Home will be attributed to the facility associated with New ESRD admission record. Patients whose initial treatment setting is Dialysis Facility/Center will be attributed to the facility immediately prior to the first treatment in a Home setting.	 Dialysis with a setting of Skilled Nursing Facility/Long Term Care Facility (SNF/LTCF) Facility type of Transplant New ESRD admission records with discharged as Acute 	<u>Baseline</u> : May 1, 2023– April 30, 2024 <u>Remeasurement</u> : May 1, 2024– March 31, 2025
Prevalent Patients Using Home Modality	Number of prevalent ESRD patients using home modality (this would include patients who move from a treatment setting of Dialysis Facility/Center to a treatment setting of Home) Due to CMS data requirements, if the count is 1–10, then the cell is blinded with "< 11."	None	Attributed to the facility associated with the Dialysis Facility/Center treatment record prior to moving to a Home setting	 Patients whose only setting during the measurement period is Home Dialysis with a setting SNF/LTCF Facility type of Transplant Patients whose most recent admission reason is Dialysis in Support of Transplant 	<u>Baseline</u> : May 1, 2023– April 30, 2024 <u>Remeasurement</u> : May 1, 2024– March 31, 2025



Measure Name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods
ESRD-Related Hospitalizations per 100 Patient Months	Count of ESRD-related inpatient hospital admissions during the remeasurement period with a Medicare claim for primary diagnosis from Appendix A	The number of patient-months where patients are being treated in a dialysis facility during the remeasurement period	Patients are attributed to the facility where treatment was received as of the most current treatment record.	 The patient-month is excluded for: Patients not in enrolled in Medicare FFS. Patients attributed to a transplant center. Patients not on dialysis at same facility as of end of the previous month. Patients discharged during month for reason of Transplanted in U.S. or Transplanted outside U.S. 	<u>Baseline</u> : May 1, 2022– April 30, 2023 <u>Remeasurement</u> : May 1, 2024– March 31, 2025
Outpatient Emergency Department Visits per 100 Patient Months	Count of ESRD-related emergency room treat-and- release visits during the remeasurement period with a Medicare claim with a primary diagnosis from Appendix A	The number of patient-months where patients are being treated in a dialysis facility during the remeasurement period	Patients are attributed to the facility where treatment was received as of the most current treatment record.	 The patient-month is excluded for: Patients not in enrolled in Medicare FFS. Patients attributed to a transplant center. Patients not on dialysis at same facility as of end of the previous month. Patients discharged during month for reason of Transplanted in U.S. or Transplanted outside U.S. 	Baseline: May 1, 2022– April 30, 2023 <u>Remeasurement</u> : May 1, 2024– March 31, 2025
Patients that are up to date for pneumococcal pneumonia vaccination	Denominator dialysis patients who are up to date for pneumococcal pneumonia vaccination, per the Centers for Disease Control and Prevention (CDC) recommendations, as reported in EQRS by the end of the remeasurement period	Patients on dialysis as of the end of the previous month who are eligible to receive a pneumococcal pneumonia vaccination	Patients are attributed to their dialysis facility at the end of the previous month. The vaccination record follows the patient. The facility where the patient is at the end of the previous month will receive the attribution.	 Patients under the age of 19 Patients not receiving dialysis as of end of measurement period Patients with Medical Reason - Allergic or Adverse Reaction reason reported in EQRS vaccination module unless they are up to date for pneumococcal pneumonia vaccination Patients with Declined - Religious/Philosophical reason reported in EQRS vaccination 	Baseline: Any pneumococcal pneumonia vaccinations in EQRS indicating an eligible patient is up to date with vaccinations by April 2023 <u>Remeasurement</u> : May 1, 2024– March 31, 2025



Measure Name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods
				 module unless they are up to date for pneumococcal pneumonia vaccination Patients with Unknown vaccination type and date of 08/06/2022 or later in EQRS vaccination module unless they are up to date for pneumococcal pneumonia vaccination 	
Patients who receive an influenza vaccination	Denominator patients who have an influenza vaccination administration date from August 2024– April 2025 in EQRS	Patients on dialysis at the end of the remeasurement period who are eligible to receive an influenza vaccination	Patients are attributed to their dialysis facility as of the end of the previous month.	 Patients not receiving dialysis as of the end of the previous month Patients with Medical Reason - Allergic or Adverse Reaction reason reported in EQRS influenza vaccination module unless they meet the definition for being included in the numerator Patients with Declined - Religious/Philosophical reason reported in EQRS influenza vaccination module unless they meet the definition for being included in the numerator 	<u>Remeasurement</u> : August 31, 2024– March 31, 2025
Data Quality— 2728 Forms Submitted On Time	Number of submitted Initial Dialysis 2728 forms due within the most recent 12 months where the submission date in EQRS is within 45 days of the Date Patient Started Chronic Dialysis at Current Facility	Number of submitted Initial Dialysis 2728 forms due within the most recent 12 months	Patients are attributed to facility submitting form.	 Facility type of Transplant Patients discharged as Acute Patients discharged as Recover Function and discharge date is before form submission date Patients discharged as "Other" or "Transplant Outside the U.S." Initial 2728 excluded if patient has a Date of Death 	Baseline: May 1, 2022– April 30, 2023 Remeasurement: Rolling 12-month period using most recent EQRS data as of March 31, 2025



Measure Name	Numerator	Denominator	Attribution	Exclusion Criteria	Measure Time Periods
Data Quality— 2746 Forms Submitted On Time	Number of 2746 forms submitted for most recent 12 months where submitted date is within fourteen (14) days of death date	Number of 2746 forms submitted for most recent 12 months	Patients are attributed to the facility submitting the form.	 Facility type of Transplant Patients discharged as Acute Patients discharged as Recover Function where discharge date is before form submission date 	Baseline: January 1, 2020– December 31, 2020 Remeasurement: Rolling 12-month period using most recent EQRS data as of March 31, 2025

Appendix A: List of Priority Diagnosis Categories

Blood Pressure Management

1161 Hypertensive Emergency1169 Hypertensive Crisis, Unspecified1160 Hypertensive Urgency

Fluid Balance-Related

E8770 Fluid overload unspecified E8779 Other fluid overload J810 Acute pulmonary edema I509 Congestive Heart Failure, Unspecified E8770 Hypervolemia I5021 Acute systolic (congestive) heart failure I5023 Acute on chronic systolic (congestive) heart failure I5031 Acute diastolic (congestive) heart failure I5033 Acute on chronic diastolic (congestive) heart failure I5041 Acute combined systolic (congestive) and diastolic (congestive) heart failure

Infection-Related

A419 Sepsis, unspecified organism A4101 Sepsis due to Methicillin Susceptible Staphylococcus aureus A4102 Sepsis due to Methicillin Resistant Staphylococcus aureus T8571 Infection and inflammatory reaction due to peritoneal dialysis catheter



T8571XA Infection and inflammatory reaction due to peritoneal dialysis catheter, initial encounter T8571XD Infection and inflammatory reaction due to peritoneal dialysis catheter, subsequent encounter T8571XS Infection and inflammatory reaction due to peritoneal dialysis catheter, sequela

- T80211 Bloodstream infection due to central venous catheter
- T80211A Bloodstream infection due to central venous catheter, initial encounter
- T80211D Bloodstream infection due to central venous catheter, subsequent encounter
- T80211S Bloodstream infection due to central venous catheter, sequela
- T827 Infection and Inflammatory Reaction due to Other Cardiac and Vascular Devices, Implants and Grafts

Anemia Management

D631 Anemia of Chronic Kidney Disease

Endocrine-Related

E162 Hypoglycemia, unspecified

Electrolyte and Mineral Metabolism Disorders

E871 Hypo-osmolality and hyponatremia E875 Hyperkalemia E876 Hypokalemia E8339 Hyper- and Hypophosphatemia E8351 Hypocalcemia E8352 Hypercalcemia

Vascular-Related

T82838 Hemorrhage due to vascular prosthetic devices, implants and grafts T82838A Hemorrhage due to vascular prosthetic devices, implants and grafts, initial encounter T82838D Hemorrhage due to vascular prosthetic devices, implants and grafts, subsequent encounter T82838S Hemorrhage due to vascular prosthetic devices, implants and grafts, sequela T82858 Stenosis of other vascular prosthetic devices, implants and grafts T82858A Stenosis of other vascular prosthetic devices, implants and grafts T82858D Stenosis of other vascular prosthetic devices, implants and grafts, initial encounter T82858D Stenosis of other vascular prosthetic devices, implants and grafts, subsequent encounter T82858D Stenosis of other vascular prosthetic devices, implants and grafts, subsequent encounter T82858S Stenosis of other vascular prosthetic devices, implants and grafts, subsequent encounter T82858S Stenosis of other vascular prosthetic devices, implants and grafts, subsequent encounter

This material was prepared by ESRD Networks 7, 13, 15, 17, and 18 under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. XS-ESRD-15N5SS-05192025-01